An interventional study of Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD) in Parkinson Disease, Idiopathic, sponsored by Adi Negev-Nahalat Eran. Recruiting at 1 site in Israel. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by Adi Negev-Nahalat Eran · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Parkinson Disease with a site in Israel — 17 open to participants now, 24 under way, 1 of them phase 3. Parkinson Disease · Israel.
Among the 124 studies in Parkinson Disease with a site in Israel, this one is the 72nd largest by planned enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2024, is one of 28 with no phase, reaches primary completion later than 5 of the 23 other live ones, and was the 117th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →17 of the 124 studies in Parkinson Disease with a site in Israel are open now. Recruiting first, the newest first:
AbbVie · Sites in Israel, United States, Canada and 6 more countries
Ages 18–69
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 40–85
KU Leuven · Sites in Israel, Belgium, Germany
Ages 18+ · Healthy volunteers
University of Kiel · Sites in Israel, Italy
Neuron23 Inc. · Sites in Israel, United States, Italy and 3 more countries
Ages 40–80
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 26 · Phase 3 26 · Phase 4 1
First in 2002; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 60 across the 84 interventional studies, 120 across the 39 observational. Of the 64 that completed or were terminated, 21 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 124 have an industry lead sponsor. The 10 most frequent:
Adi Negev-Nahalat Eran is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Adi Negev-Nahalat Eran has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Parkinson Disease with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06602193Denali Therapeutics Inc.Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | 2027-03 |
| NCT07580612KU LeuvenAID-FOG: Artificial Intelligence-Driven Freezing of Gait Detection in the Home | 2027-06 |
| NCT04994015Parkinson's FoundationParkinson's Foundation PD GENEration Genetic Registry | 2027-07-01 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 124 studies in Parkinson Disease with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to test a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD). This pilot experiment will involve the collection of both subjective user evaluation measures and objective motor and cognitive measures.
Participants \& Protocol:
Recruitment: Advertising ads in movement disorders units in hospitals and medical centers in the south, as well as through the help of the Parkinson's Association.
The study will be conducted with 15 PD patients, aged 50-75, at the Adi Negev Clinic. Each patient will use the robotic system five times, with each session lasting 30 minutes. The intervention plan incorporates principles of effective rehabilitation practice, including repeated practice, goal-oriented practice, variable difficulty, rhythmic cueing, and social interaction. Before the research begins, participants will sign an informed consent form.
Baseline and Pre-Post Tests:
Assessments including the MoCA, demographic data, clinical data, Color Trails Test (CTT), motor UPDRS, Box \& Blocks Test, and Cognitive Reserve Index Questionnaire (CRIq) will be collected before the first session by an occupational or physical therapist. After the fifth session, post-intervention assessments will include motor UPDRS, Box \& Blocks Test, CTT, System Usability Scale (SUS), Intrinsic Motivation Inventory (IMI), and a satisfaction questionnaire.
Hypothesis:
It is hypothesized that motor and cognitive training using the robots will improve the patients' clinical symptoms, as evidenced by pre-post test results.
Novelty \& Impact:
This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres. Additionally, this study will be the first to use the Cognitive Reserve Index Questionnaire (CRIq) in Hebrew for people with PD. The potential impact of this project is twofold: testing a new rehabilitation tool and a screening tool for PD patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We will run a robotic exercise game with 15 PD patients who will use the system in a sitting position. Each patient will use the system 5 times, each time for 30 min. Principles of effective rehabilitation practice such as repetitive practice, goal-oriented practice, variable difficulty, rhythmic cueing, and social interaction are implemented in our design
Device: Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)
This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
level of engagement
We will ask participants to rate their perceived level of engagement with the platform.
Time frame: 2 Mon
improvement in UPDRS
We will perform post-intervention assessments which include motor UPDRS (Unified Parkinson Disease Rating Scale)
Time frame: 4 Mon
improvement in fine motor coordination
We will perform post-intervention assessments which include Box and Blocks Test for fine motor coordination.
Time frame: 4 Mon
improvement in CTT (Color Trail Test)
We will perform post-intervention assessments which include CTT (Color Trail Test) for executive functions.
Time frame: 4 Mon
Testing the usability of use of the system
We will perform post-intervention assessments which include System Usability Scale (SUS).
Time frame: 4 Mon
Measuring the motivation to use the system
We will perform post-intervention assessments which include the Intrinsic Motivation Inventory (IMI).
Time frame: 4 Mon
Started Dec 2024 (actual). Primary completion is estimated for Mar 2025, 3 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 3 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adi Negev-Nahalat Eran